Context: The sFlt-1/PlGF ratio blood test can aid the prediction of preeclampsia (PE) in advance of a clinical diagnosis. Gestational diabetes mellitus (GDM) predisposes to PE, but may influence levels of these biomarkers independently of PE.
Objective: To determine whether the sFlt-1/PlGF ratio retains its clinical utility to predict PE in patients with GDM.
Design: Retrospective analysis of sFlt-1/PlGF ratio and associated clinical outcome data acquired between September 2016 and September 2022.
Setting: The Royal Women's Hospital, Melbourne, Australia.
Patients: 1,416 sFlt-1/PlGF ratio results from pregnant women with and without GDM, and with and without PE, referred for sFlt-1/PlGF testing.
Intervention: N/A.
Main outcome measure: sFlt-1, PlGF and sFlt-1/PlGF ratio test results in relation to PE and GDM.
Results: There were no significant differences in the AUC, specificity, sensitivity, PPV or NPV between the PE + No GDM and PE + GDM groups in both the 0-7 and 8-14 day before delivery categories. In the 0-7 day category the PE + No GDM group had a AUC of 0.82 (95% CI: 0.79-0.87), sensitivity of 85.3% (95% CI: 80.8% - 89.1%), NPV of 92.7% (95% CI: 90.5% - 94.5%), and the PE + GDM group had an AUC of 0.87 (95% CI: 0.82-0.93), sensitivity of 89.4% (95% CI: 76.9% - 96.5%) and NPV of 94.8% (95% CI: 88.7% - 97.7%).
Conclusions: The results of this investigation indicate that whilst GDM may lead to changes in the sFlt-1/PlGF ratio, the sFlt-1/PlGF ratio test retains its clinical utility in predicting PE onset.
Keywords: Gestational Diabetes Mellitus; PlGF; Preeclampsia; sFlt-1; sFlt-1/PlGF ratio.
© The Author(s) 2025. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. See the journal About page for additional terms.